egf (lyophilized) Search Results


human egf  (Revvity)
91
Revvity human egf
A-C: Quantification of the relative extent of HPEKp in the seam <t>between</t> <t>spheroids</t> (a metric established to quantify the progression of fusion) with HWJSCs (mean ± SEM for 6 replicates aggregated from 2 independent experiments), normalized to the day 0 time point, upon treatment with either DMSO (0.1%), CH5183284 (20 μM) (A.i), Erlotinib (6.5 μM) (B.i), or SB431542 (10 μM) (C.i). The DMSO control is shown on all three graphs for comparison. Asterisks denote statistical significance relative to DMSO at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). Fluorescent micrographs represent a single representative z-plane (~55–60μm from the bottom of the amalgam of fusing spheroids) after 4 days of fusion in the presence of CH5183284 (A.ii), Erlotinib (B.ii), or SB431542 (C.ii). White asterisks denote HPEKp in the seam between adjacent spheroids. D: Relative cellular ATP content of HPEKp/HWJSC spheroids after 4 days of fusion as quantified using CellTiter Glo 3D assay following the manufacturer’s instructions, normalized to the DMSO control and presented as mean ± SEM for at least 12 replicates aggregated from 2 at least independent experiments. E: Quantification of the relative extent of HPEKp in the seam between spheroids, normalized to the day 0 time point, upon treatment with either vehicle control (white) or human recombinant <t>EGF</t> at 2 ng/mL (green), 10 ng/mL (blue), or 50 ng/mL (black) and presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. Asterisk denotes statistical significance relative to control at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). F: Area under the curve analysis of EGF-treated spheroids throughout fusion, tabulated using the trapezoid method, presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. The vehicle control (0 ng/mL EGF) is displayed as 0.1 ng/mL in the figure. Asterisk denotes statistical significance relative to control with one-way ANOVA and Fisher’s least significant difference test (α = 0.05).
Human Egf, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human egf/product/Revvity
Average 91 stars, based on 1 article reviews
human egf - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
lyophilized murine egf  (PeproTech)
90
PeproTech lyophilized murine egf
A-C: Quantification of the relative extent of HPEKp in the seam <t>between</t> <t>spheroids</t> (a metric established to quantify the progression of fusion) with HWJSCs (mean ± SEM for 6 replicates aggregated from 2 independent experiments), normalized to the day 0 time point, upon treatment with either DMSO (0.1%), CH5183284 (20 μM) (A.i), Erlotinib (6.5 μM) (B.i), or SB431542 (10 μM) (C.i). The DMSO control is shown on all three graphs for comparison. Asterisks denote statistical significance relative to DMSO at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). Fluorescent micrographs represent a single representative z-plane (~55–60μm from the bottom of the amalgam of fusing spheroids) after 4 days of fusion in the presence of CH5183284 (A.ii), Erlotinib (B.ii), or SB431542 (C.ii). White asterisks denote HPEKp in the seam between adjacent spheroids. D: Relative cellular ATP content of HPEKp/HWJSC spheroids after 4 days of fusion as quantified using CellTiter Glo 3D assay following the manufacturer’s instructions, normalized to the DMSO control and presented as mean ± SEM for at least 12 replicates aggregated from 2 at least independent experiments. E: Quantification of the relative extent of HPEKp in the seam between spheroids, normalized to the day 0 time point, upon treatment with either vehicle control (white) or human recombinant <t>EGF</t> at 2 ng/mL (green), 10 ng/mL (blue), or 50 ng/mL (black) and presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. Asterisk denotes statistical significance relative to control at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). F: Area under the curve analysis of EGF-treated spheroids throughout fusion, tabulated using the trapezoid method, presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. The vehicle control (0 ng/mL EGF) is displayed as 0.1 ng/mL in the figure. Asterisk denotes statistical significance relative to control with one-way ANOVA and Fisher’s least significant difference test (α = 0.05).
Lyophilized Murine Egf, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lyophilized murine egf/product/PeproTech
Average 90 stars, based on 1 article reviews
lyophilized murine egf - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
lyophilized egf peprotech 100-15  (PeproTech)
90
PeproTech lyophilized egf peprotech 100-15
A-C: Quantification of the relative extent of HPEKp in the seam <t>between</t> <t>spheroids</t> (a metric established to quantify the progression of fusion) with HWJSCs (mean ± SEM for 6 replicates aggregated from 2 independent experiments), normalized to the day 0 time point, upon treatment with either DMSO (0.1%), CH5183284 (20 μM) (A.i), Erlotinib (6.5 μM) (B.i), or SB431542 (10 μM) (C.i). The DMSO control is shown on all three graphs for comparison. Asterisks denote statistical significance relative to DMSO at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). Fluorescent micrographs represent a single representative z-plane (~55–60μm from the bottom of the amalgam of fusing spheroids) after 4 days of fusion in the presence of CH5183284 (A.ii), Erlotinib (B.ii), or SB431542 (C.ii). White asterisks denote HPEKp in the seam between adjacent spheroids. D: Relative cellular ATP content of HPEKp/HWJSC spheroids after 4 days of fusion as quantified using CellTiter Glo 3D assay following the manufacturer’s instructions, normalized to the DMSO control and presented as mean ± SEM for at least 12 replicates aggregated from 2 at least independent experiments. E: Quantification of the relative extent of HPEKp in the seam between spheroids, normalized to the day 0 time point, upon treatment with either vehicle control (white) or human recombinant <t>EGF</t> at 2 ng/mL (green), 10 ng/mL (blue), or 50 ng/mL (black) and presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. Asterisk denotes statistical significance relative to control at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). F: Area under the curve analysis of EGF-treated spheroids throughout fusion, tabulated using the trapezoid method, presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. The vehicle control (0 ng/mL EGF) is displayed as 0.1 ng/mL in the figure. Asterisk denotes statistical significance relative to control with one-way ANOVA and Fisher’s least significant difference test (α = 0.05).
Lyophilized Egf Peprotech 100 15, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lyophilized egf peprotech 100-15/product/PeproTech
Average 90 stars, based on 1 article reviews
lyophilized egf peprotech 100-15 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
lyophilized human recombinant egf  (PeproTech)
90
PeproTech lyophilized human recombinant egf
A-C: Quantification of the relative extent of HPEKp in the seam <t>between</t> <t>spheroids</t> (a metric established to quantify the progression of fusion) with HWJSCs (mean ± SEM for 6 replicates aggregated from 2 independent experiments), normalized to the day 0 time point, upon treatment with either DMSO (0.1%), CH5183284 (20 μM) (A.i), Erlotinib (6.5 μM) (B.i), or SB431542 (10 μM) (C.i). The DMSO control is shown on all three graphs for comparison. Asterisks denote statistical significance relative to DMSO at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). Fluorescent micrographs represent a single representative z-plane (~55–60μm from the bottom of the amalgam of fusing spheroids) after 4 days of fusion in the presence of CH5183284 (A.ii), Erlotinib (B.ii), or SB431542 (C.ii). White asterisks denote HPEKp in the seam between adjacent spheroids. D: Relative cellular ATP content of HPEKp/HWJSC spheroids after 4 days of fusion as quantified using CellTiter Glo 3D assay following the manufacturer’s instructions, normalized to the DMSO control and presented as mean ± SEM for at least 12 replicates aggregated from 2 at least independent experiments. E: Quantification of the relative extent of HPEKp in the seam between spheroids, normalized to the day 0 time point, upon treatment with either vehicle control (white) or human recombinant <t>EGF</t> at 2 ng/mL (green), 10 ng/mL (blue), or 50 ng/mL (black) and presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. Asterisk denotes statistical significance relative to control at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). F: Area under the curve analysis of EGF-treated spheroids throughout fusion, tabulated using the trapezoid method, presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. The vehicle control (0 ng/mL EGF) is displayed as 0.1 ng/mL in the figure. Asterisk denotes statistical significance relative to control with one-way ANOVA and Fisher’s least significant difference test (α = 0.05).
Lyophilized Human Recombinant Egf, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lyophilized human recombinant egf/product/PeproTech
Average 90 stars, based on 1 article reviews
lyophilized human recombinant egf - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
egf (lyophilized)  (PeproTech)
90
PeproTech egf (lyophilized)
A-C: Quantification of the relative extent of HPEKp in the seam <t>between</t> <t>spheroids</t> (a metric established to quantify the progression of fusion) with HWJSCs (mean ± SEM for 6 replicates aggregated from 2 independent experiments), normalized to the day 0 time point, upon treatment with either DMSO (0.1%), CH5183284 (20 μM) (A.i), Erlotinib (6.5 μM) (B.i), or SB431542 (10 μM) (C.i). The DMSO control is shown on all three graphs for comparison. Asterisks denote statistical significance relative to DMSO at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). Fluorescent micrographs represent a single representative z-plane (~55–60μm from the bottom of the amalgam of fusing spheroids) after 4 days of fusion in the presence of CH5183284 (A.ii), Erlotinib (B.ii), or SB431542 (C.ii). White asterisks denote HPEKp in the seam between adjacent spheroids. D: Relative cellular ATP content of HPEKp/HWJSC spheroids after 4 days of fusion as quantified using CellTiter Glo 3D assay following the manufacturer’s instructions, normalized to the DMSO control and presented as mean ± SEM for at least 12 replicates aggregated from 2 at least independent experiments. E: Quantification of the relative extent of HPEKp in the seam between spheroids, normalized to the day 0 time point, upon treatment with either vehicle control (white) or human recombinant <t>EGF</t> at 2 ng/mL (green), 10 ng/mL (blue), or 50 ng/mL (black) and presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. Asterisk denotes statistical significance relative to control at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). F: Area under the curve analysis of EGF-treated spheroids throughout fusion, tabulated using the trapezoid method, presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. The vehicle control (0 ng/mL EGF) is displayed as 0.1 ng/mL in the figure. Asterisk denotes statistical significance relative to control with one-way ANOVA and Fisher’s least significant difference test (α = 0.05).
Egf (Lyophilized), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egf (lyophilized)/product/PeproTech
Average 90 stars, based on 1 article reviews
egf (lyophilized) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
lyophilized mouse-derived egf crepidermal growth factor  (Collaborative Research Inc)
90
Collaborative Research Inc lyophilized mouse-derived egf crepidermal growth factor
A-C: Quantification of the relative extent of HPEKp in the seam <t>between</t> <t>spheroids</t> (a metric established to quantify the progression of fusion) with HWJSCs (mean ± SEM for 6 replicates aggregated from 2 independent experiments), normalized to the day 0 time point, upon treatment with either DMSO (0.1%), CH5183284 (20 μM) (A.i), Erlotinib (6.5 μM) (B.i), or SB431542 (10 μM) (C.i). The DMSO control is shown on all three graphs for comparison. Asterisks denote statistical significance relative to DMSO at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). Fluorescent micrographs represent a single representative z-plane (~55–60μm from the bottom of the amalgam of fusing spheroids) after 4 days of fusion in the presence of CH5183284 (A.ii), Erlotinib (B.ii), or SB431542 (C.ii). White asterisks denote HPEKp in the seam between adjacent spheroids. D: Relative cellular ATP content of HPEKp/HWJSC spheroids after 4 days of fusion as quantified using CellTiter Glo 3D assay following the manufacturer’s instructions, normalized to the DMSO control and presented as mean ± SEM for at least 12 replicates aggregated from 2 at least independent experiments. E: Quantification of the relative extent of HPEKp in the seam between spheroids, normalized to the day 0 time point, upon treatment with either vehicle control (white) or human recombinant <t>EGF</t> at 2 ng/mL (green), 10 ng/mL (blue), or 50 ng/mL (black) and presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. Asterisk denotes statistical significance relative to control at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). F: Area under the curve analysis of EGF-treated spheroids throughout fusion, tabulated using the trapezoid method, presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. The vehicle control (0 ng/mL EGF) is displayed as 0.1 ng/mL in the figure. Asterisk denotes statistical significance relative to control with one-way ANOVA and Fisher’s least significant difference test (α = 0.05).
Lyophilized Mouse Derived Egf Crepidermal Growth Factor, supplied by Collaborative Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lyophilized mouse-derived egf crepidermal growth factor/product/Collaborative Research Inc
Average 90 stars, based on 1 article reviews
lyophilized mouse-derived egf crepidermal growth factor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


A-C: Quantification of the relative extent of HPEKp in the seam between spheroids (a metric established to quantify the progression of fusion) with HWJSCs (mean ± SEM for 6 replicates aggregated from 2 independent experiments), normalized to the day 0 time point, upon treatment with either DMSO (0.1%), CH5183284 (20 μM) (A.i), Erlotinib (6.5 μM) (B.i), or SB431542 (10 μM) (C.i). The DMSO control is shown on all three graphs for comparison. Asterisks denote statistical significance relative to DMSO at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). Fluorescent micrographs represent a single representative z-plane (~55–60μm from the bottom of the amalgam of fusing spheroids) after 4 days of fusion in the presence of CH5183284 (A.ii), Erlotinib (B.ii), or SB431542 (C.ii). White asterisks denote HPEKp in the seam between adjacent spheroids. D: Relative cellular ATP content of HPEKp/HWJSC spheroids after 4 days of fusion as quantified using CellTiter Glo 3D assay following the manufacturer’s instructions, normalized to the DMSO control and presented as mean ± SEM for at least 12 replicates aggregated from 2 at least independent experiments. E: Quantification of the relative extent of HPEKp in the seam between spheroids, normalized to the day 0 time point, upon treatment with either vehicle control (white) or human recombinant EGF at 2 ng/mL (green), 10 ng/mL (blue), or 50 ng/mL (black) and presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. Asterisk denotes statistical significance relative to control at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). F: Area under the curve analysis of EGF-treated spheroids throughout fusion, tabulated using the trapezoid method, presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. The vehicle control (0 ng/mL EGF) is displayed as 0.1 ng/mL in the figure. Asterisk denotes statistical significance relative to control with one-way ANOVA and Fisher’s least significant difference test (α = 0.05).

Journal: PLoS ONE

Article Title: Engineering human cell spheroids to model embryonic tissue fusion in vitro

doi: 10.1371/journal.pone.0184155

Figure Lengend Snippet: A-C: Quantification of the relative extent of HPEKp in the seam between spheroids (a metric established to quantify the progression of fusion) with HWJSCs (mean ± SEM for 6 replicates aggregated from 2 independent experiments), normalized to the day 0 time point, upon treatment with either DMSO (0.1%), CH5183284 (20 μM) (A.i), Erlotinib (6.5 μM) (B.i), or SB431542 (10 μM) (C.i). The DMSO control is shown on all three graphs for comparison. Asterisks denote statistical significance relative to DMSO at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). Fluorescent micrographs represent a single representative z-plane (~55–60μm from the bottom of the amalgam of fusing spheroids) after 4 days of fusion in the presence of CH5183284 (A.ii), Erlotinib (B.ii), or SB431542 (C.ii). White asterisks denote HPEKp in the seam between adjacent spheroids. D: Relative cellular ATP content of HPEKp/HWJSC spheroids after 4 days of fusion as quantified using CellTiter Glo 3D assay following the manufacturer’s instructions, normalized to the DMSO control and presented as mean ± SEM for at least 12 replicates aggregated from 2 at least independent experiments. E: Quantification of the relative extent of HPEKp in the seam between spheroids, normalized to the day 0 time point, upon treatment with either vehicle control (white) or human recombinant EGF at 2 ng/mL (green), 10 ng/mL (blue), or 50 ng/mL (black) and presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. Asterisk denotes statistical significance relative to control at each time point with two-way ANOVA and Dunnett post-hoc test (α = 0.05). F: Area under the curve analysis of EGF-treated spheroids throughout fusion, tabulated using the trapezoid method, presented as mean ± SEM for 14 replicates aggregated from 4 independent experiments. The vehicle control (0 ng/mL EGF) is displayed as 0.1 ng/mL in the figure. Asterisk denotes statistical significance relative to control with one-way ANOVA and Fisher’s least significant difference test (α = 0.05).

Article Snippet: Alternatively, spheroids were treated at day 0 with various concentrations of recombinant human EGF (BioLegend) that was reconstituted at 10 μg/mL in sterile 1% BSA in DPBS, diluted with 1% BSA in DPBS, and added to spheroids at either 2, 10, or 50 ng/mL final concentration in CnT-PR-CC with 1% antibiotic-antimycotic, with the vehicle control containing the same dilution of 1% BSA in DPBS.

Techniques: Control, Comparison, Recombinant